Challenges and advances in the treatment of AKI

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 877-883

  Kaushal, Gur P ^a   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 7 FLUORO 9 METHYL 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; ALKALINE PHOSPHATASE; ALPHA INTERMEDIN; BONE MORPHOGENETIC PROTEIN; CREATININE; CYTOKINE RECEPTOR AGONIST; FREE RADICAL; IRON; QPI 1002; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CELL THERAPY; CONTINUOUS RENAL REPLACEMENT THERAPY; COST OF ILLNESS; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; HEART SURGERY; HUMAN; INFUSION PUMP; KIDNEY CELL; KIDNEY EPITHELIUM; KIDNEY ISCHEMIA; MEDICARE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; EMERGING THERAPIES; NEPHROLOGY;

ACUTE KIDNEY INJURY; EMERGING THERAPIES; END-STAGE KIDNEY DISEASE;

ACUTE KIDNEY INJURY; HUMANS; NEPHROLOGY;

EID: 84906555341     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013070780     Document Type: Review

References (49)

1. Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM: Evidence of autocrine modulation ofmacrophage nitric oxide synthase by alphα-melanocyte-stimulating hormone. Proc Natl Acad Sci U S A 92: 8016-8020, 1995
2. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA: Alphα-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 99: 1165-1172, 1997
3. Doi K, Hu X, Yuen PST, Leelahavanichkul A, Yasuda H, Kim SM, Schnermann J, Jonassen TE, Frøkiaer J, Nielsen S, Star RA: AP214, an analogue of alphα-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 73: 1266-1274, 2008
4. Steinbruchel D, Kirkegaard H, Beckert M, Nielsen S, Pallesen PA: AP214 improves long-term (3 month) outcome on composite endpoint of death, renal replacement therapy or reduced kidney function in patients undergoing cardiac surgery in a phase 2 clinical trial. [abstract] Clin J Am Soc Nephrol 22: 184A, 2011
5. ClinicalTrials.gov: A safety and efficacy trial of multiple dosing regimens of ABT-719 for the prevention of acute kidney injury in subjects undergoing high risk cardiac surgery. NCT01777165 Jan 24, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01777165. Accessed February 1, 2013
6. ClinicalTrials.gov: A safety and efficacy trial of multiple dosing regimens of ABT-719 for the prevention of acute kidney injury in subjects undergoing high risk major surgery. NCT01777165 May 10, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01897519. Accessed November 19, 2013
7. Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC: P53mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: Protective role of a p53 inhibitor. J Am Soc Nephrol 14: 128-138, 2003
8. WeiQ, DongG, Yang T,Megyesi J, Price PM, Dong Z: Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293: F1282-F1291, 2007
9. Thompson JD, Kornbrust DJ, Foy JW-D, Solano ECR, Schneider DJ, Feinstein E, Molitoris BA, Erlich S: Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 22: 255-264, 2012
10. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Thompson JD, Kalinski H, Skaliter R, Erlich S, Feinstein E: siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20: 1754-1764, 2009
11. ClinicalTrials.gov: A phase I, randomized, double-blind, dose escalation trial of the safety and pharmacokinetics of a single intravenous injection of 15NP in patients undergoing major cardiovascular surgery. NCT00554359. November 4, 2007. Available at: http://clinicaltrials.gov/ct2/show/NCT00554359. Accessed February 22, 2011
12. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, ZeisbergM, Kalluri R: Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18: 396-404, 2012
13. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK: Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102: 202-214, 1998
14. ClinicalTrials.gov: A multi-center, parallelgroup, randomized, double blind, adaptive study investigating the safety and efficacy of THR-184 in patients at increased risk of developing cardiac surgery associated-acute kidney injury (CSA-AKI).NCT01830920. April 10, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01830920. Accessed July 3, 2013
15. Tögel FE,Westenfelder C: Kidney protection and regeneration following acute injury: Progress through stem cell therapy. Am J Kidney Dis 60: 1012-1022, 2012
16. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31-F42, 2005
17. Morigi M, Benigni A: Mesenchymal stem cells and kidney repair. Nephrol Dial Transplant 28: 788-793, 2013
18. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G: Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20: 1053-1067, 2009
19. ClinicalTrials.gov: A study to evaluate the safety and efficacy of AC607 for the treatment of kidney injury in cardiac surgery subjects (ACT-AKI). NCT01602328. May 17, 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01602328. Accessed July 21, 2013
20. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord SD: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. AmJ KidneyDis 61: 649-672, 2013
21. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators: Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 124: 1260-1269, 2011
22. ClinicalTrials.gov: RenalGuard and Contrast Media (REMEDIAL II).NCT01098032. April 1, 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT01098032. Accessed July 23, 2013
23. Pickkers P, Heemskerk S, Schouten J, Laterre P-F, Vincent J-L, Beishuizen A, Jorens PG, Spapen H, Bulitta M, Peters WH, van der Hoeven JG:Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: A prospective randomized double-blind placebocontrolled trial. Crit Care 16: R14, 2012
24. Ince C, Ergin b, van Elsas AV: Recombinant alkaline phosphatase modulates inflammation and injury in two ratmodels of AKI. [abstract] J Am Soc Nephrol 24: 380A, 2013
25. Halliwell B, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186: 1-85, 1990
26. Rajapurkar MM, Baliga R, Shah SV: Catalytic (labile) iron in kidney disease. In: Seldin and Giebisch's The Kidney, Physiology & Pathophysiology, 5th Ed., edited by Alpern RJ, Caplan MJ, Moe OW, San Diego, Elsevier Inc., Academic Press, 2012, pp 3003-3015
27. ClinicalTrials.gov: Deferiprone for the prevention of contrast-induced acute kidney injury. NCT01146925 June 16, 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT01146925. Accessed November 13, 2013
28. Devarajan P: Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17: 1503-1520, 2006
29. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P: Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 15: 3073-3082, 2004
30. Ganz T, Nemeth E: Hepcidin and disorders of iron metabolism. Annu Rev Med 62: 347-360, 2011
31. Haase M, Bellomo R, Haase-Fielitz A: Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol 55: 2024-2033, 2010
32. Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, Nickerson PW, Rigatto C: Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol 6: 2340-2346, 2011
33. Pino CJ, Yevzlin AS, Lee K, Westover AJ, Smith PL, Buffington DA, Humes HD: Cellbased approaches for the treatment of systemic inflammation. Nephrol Dial Transplant 28: 296-302, 2013
34. Tumlin J, Wali R, Williams W, Murray PT, Tolwani AJ, Vinnikova AK, Szerlip HM, Ye J, Paganini EP, Dworkin L, Finkel KW, Kraus MA, Humes HD: Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 19: 1034-1040, 2008
35. Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, DaSilva JR, Astor BC, Yevzlin AS, Humes HD: The effect of the selective cytopheretic devise on acute kidney injury outcomes in the intensive care unit: A multicenter pilot study. Sem Dial 26, 2012.
36. Buffington DA, Pino CJ, Chen L, Westover AJ, Hageman G, Humes HD: Bioartificial Renal Epithelial Cell System (BRECS): A compact, cryopreservable extracorporeal renal replacement device. Cell Med 4: 33-43, 2012
37. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD; Acute Kidney Injury Advisory Group of the American Society of Nephrology: Ongoing clinical trials in AKI. Clin J Am Soc Nephrol 7: 861-873, 2012
38. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, PalevskyPM: Prevention of contrastinduced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8: 1618-1631, 2013
39. Endre ZH, Pickering JW: Acute kidney injury clinical trial design: Old problems, new strategies. Pediatr Nephrol 28: 207-217, 2013
40. Bonventre JV, Basile D, Liu KD, McKay D, Molitoris BA, Nath KA, Nickolas TL, Okusa MD, Palevsky PM, Schnellmann R, Rys-Sikora K, Kimmel PL, Star RA; Kidney Research National Dialogue (KRND): AKI: A path forward. Clin J Am Soc Nephrol 8: 1606-1608, 2013
41. Chawla LS: Acute kidney injury leading to chronic kidney disease and long-term outcomes of acute kidney injury: The best opportunity to mitigate acute kidney injury? Contrib Nephrol 174: 182-190, 2011
42. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20: 223-228, 2009
43. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302: 1179-1185, 2009
44. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordon;ez JD, Hsu CY: Dialysisrequiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 76: 893-899, 2009
45. Chawla LS, Kimmel PL: Acute kidney injury and chronic kidney disease: An integrated clinical syndrome. Kidney Int 82: 516-524, 2012
46. Hsu CY, Vittinghoff E, Lin F, Shlipak MG: The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141: 95-101, 2004
47. GoAS, Parikh CR, Ikizler TA, Coca S, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Zappitelli M, Liu KD, Reeves WB, Ghahramani N, Devarajan P, Faulkner GB, Tan TC, Kimmel PL, Eggers P, Stokes JB; Assessment Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury Study Investigators: The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: Design and methods. BMC Nephrol 11: 22, 2010
48. Kramer MR: Catalytic philanthropy. Stanford Social Innovation Review Fall 2009; 7. Available at: http://www.ssireview.org/articles/entry/catalytic-philanthropy. Accessed June 28, 2013/
49. United States Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012